Publicaciones en colaboración con investigadores/as de Hospital General de Granollers (18)

2024

  1. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 9, pp. 1189-1199

  2. Similarities and differences between systemic juvenile idiopathic arthritis and adult-onset Still’s disease: a multicenter Spanish study

    Rheumatology International

2023

  1. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study

    RMD open, Vol. 9, Núm. 1

  2. Immunoglobulins in systemic sclerosis management. A large multicenter experience

    Autoimmunity Reviews, Vol. 22, Núm. 11

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  2. Interobserver reliability of Masei index validation by a multicenter collaborative group of rheumatologists

    Rheumatology International, Vol. 42, Núm. 3, pp. 441-448

  3. Myo-Spain: Spanish Registry of Patients with Idiopathic Inflammatory Myopathy. Methodology

    Reumatologia Clinica, Vol. 18, Núm. 5, pp. 253-259

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Measuring inflammation in rheumatoid arthritis with a new clinical and ultrasound index: development and initial validation

    Rheumatology International, Vol. 39, Núm. 12, pp. 2137-2145

2016

  1. LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition

    Clinical and Experimental Rheumatology

2015

  1. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35

  2. Efficacy of anakinra in refractory adult-onset still's disease multicenter study of 41 patients and literature review

    Medicine (United States), Vol. 94, Núm. 39, pp. e1554

2014

  1. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility

    Arthritis Research and Therapy, Vol. 16, Núm. 1

  2. Bone mineral density status and frequency of osteoporosis and clinical fractures in 155 patients with psoriatic arthritis followed in a university hospital

    Reumatologia Clinica, Vol. 10, Núm. 2, pp. 89-93

2011

  1. Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry.

    Rheumatology (Oxford, England), Vol. 50, Núm. 11, pp. 1999-2004

  2. Revisión sistemática: eficacia y seguridad del tratamiento anti-TNF en pacientes ancianos

    Reumatologia Clinica

2010

  1. Power doppler ultrasonography assessment of entheses in spondyloarthropathies: Response to therapy of entheseal abnormalities

    Journal of Rheumatology, Vol. 37, Núm. 10, pp. 2110-2117

2006

  1. Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period

    Arthritis Research and Therapy, Vol. 8, Núm. 1